JPRN-UMIN000011079已完成未知
Combination therapy of radiation and intratumoral directo injection of dendritic cells for advanced esophageal cancer, a phase I study. - Chiba RT-DC therapy
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Previous immunotehrapy, previous radiation therapy 2.Fistula 3.Obvious infection 4.Alb 3.0mg/ml or less 5.Uncontrolable pleural effusion, ascites, pericardial effusion 6.Severe heart failure 7.Respiratory or other complications 8.Psychological disorders 9.Active double cancers 10.Steroid usage 11.Hepatitis B or C. HIV, HTLV-1 positive 12.Hypersensitivity for albumin 13.Pregnant woman 14.Autoimmune diseases 16.Patients who cannot undergo apheresis.
研究者
相似试验
进行中（未招募）
不适用
Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter, open-label, Phase II studypatients with newly diagnosed glioblastoma (GBM) without methylation of the DNA-repair enzyme O6-methylguanin-DNA-methyltransferase (MGMT) gene promoterMedDRA version: 9.1Level: LLTClassification code 10006153Term: Brain tumorEUCTR2008-003003-31-NLEORTC Headquarters108
进行中（未招募）
不适用
Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter, open-label, Phase II studypatients with newly diagnosed glioblastoma (GBM) without methylation of the DNA-repair enzyme O6-methylguanin-DNA-methyltransferase (MGMT) gene promoterMedDRA version: 9.1Level: LLTClassification code 10006153Term: Brain tumorEUCTR2008-003003-31-ATEORTC Headquarters108
进行中（未招募）
不适用
Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter a randomized multicenter, open-label, Phase II study. - NDpatients with newly diagnosed glioblastoma without methylation of the MGMT gene promotorMedDRA version: 12.0Level: LLTClassification code 10018336Term: GlioblastomaEUCTR2008-003003-31-ITE.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER108
进行中（未招募）
不适用
Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter, open-label, Phase II studypatients with newly diagnosed glioblastoma (GBM) without methylation of the DNA-repair enzyme O6-methylguanin-DNA-methyltransferase (MGMT) gene promoterMedDRA version: 13.1Level: LLTClassification code 10006153Term: Brain tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-003003-31-DEEORTC Headquarters108
进行中（未招募）
1 期
Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter, open-label, Phase II studypatients with newly diagnosed glioblastoma (GBM) without methylation of the DNA-repair enzyme O6-methylguanin-DNA-methyltransferase (MGMT) gene promoterMedDRA version: 13.1 Level: LLT Classification code 10006153 Term: Brain tumor System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-003003-31-GBEORTC Headquarters111